Publication Date

2018

Abstract

KEY POINTS
- Heart failure is a common comorbidity in diabetes and patients with both conditions have a particularly poor prognosis.
- Most clinical outcome trials investigating the effects of glucose-lowering agents have excluded patients with heart failure.
- Glitazones and, possibly, some dipeptidyl peptidase-4 inhibitors, cause an increased risk of developing heart failure and deterioration in existing heart failure.
- One class of drugs, the sodium glucose cotransporter 2 inhibitors, reduce the risk of developing heart failure.

School/Institute

Mary MacKillop Institute for Health Research

Document Type

Journal Article

Access Rights

ERA Access

Access may be restricted.

Share

COinS